Voluntary announcement- phase iii clinical study data of xuanzhu biopharm's anaprazole sodium for reflux esophagitis presented at ueg week 2026
Filed with HKEX · Stock code 460 ·
6ix is reading this filing.
View original source (HKEXnews)Sihuan Pharmaceutical Holdings Group Ltd. on 6ix
Earlier from Sihuan Pharmaceutical
- Voluntary announcement - polycaprolactone microsphere facial filler for injection and hyaluronic acid sodium composite solution for injection independently developed by meiyan space, a subsidiary of Sihuan Pharmaceutical, approved for market launch in hong kong
- Voluntary announcement-Sihuan Pharmaceutical completed a strategic investment in canton biologics to enhance the layout of the entire industrial chain of regenerative medical aesthetics
- Voluntary announcement - new specifications of skin booster (brand name: dongyan) of Sihuan Pharmaceutical approved for launch by nmpa
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Notification Letter and Request Form to Non-registered Holder
Follow Sihuan Pharmaceutical into a list and get an email when it puts out news.
Follow Sihuan Pharmaceutical